Correcting and Replacing: Theralase(R) Releases Q2 2026 Financial Statements
Theralase® Provides Updates on its Phase II Bladder Cancer Clinical Study and Oncology PipelineThis Press Release adds omitted safety and prescribing information about Adstiladrin® (nadofaragene firadenovec-vncg)Toronto, Ontario--(Newsfile Corp. - September 18, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical-stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and...